CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 136 enrolled
Drug / intervention
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05283395
NCT05283395Phase 4Completed
CompareCT.gov

A Multicenter, Open-Label Rocklatan® (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension

Aerie Pharmaceuticals·interventional·Posted Mar 17, 2022·Updated Apr 3, 2024

In Brief

A Phase 4 clinical trial evaluating Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution for Glaucoma. Completed, enrolled 136 participants across 21 sites.

Detailed Summary

The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedMar 17, 2022
Enrollment StartMar 28, 2022
Primary CompletionMar 22, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.3 years ago

Interventions

Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solutiondrug

Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension